$4.75 Million Settlement Reached in Rexulti Class-Action Lawsuit

Lawyers representing patients involved in a class-action lawsuit concerning the drug Rexulti have announced a settlement of $4.75 million. This agreement benefits individuals who were prescribed the medication and who experienced compulsive behaviors or impulse-control disorders, such as compulsive gambling, hypersexuality, compulsive spending, and binge-eating.

The lawsuit encompasses anyone in Canada who received a prescription for Rexulti from February 16, 2017, to the present. Rexulti is an antipsychotic medication primarily used to treat schizophrenia and depression.

Details of the Settlement

According to a notice released by the Toronto law firm Rochon Genova, the Quebec Superior Court has yet to determine the merits of the claims involved in this lawsuit. The settlement is described as a compromise of disputed claims, and it does not imply any admission of liability or wrongdoing by the defendants.

The national class action was authorized by the Quebec Superior Court in 2024 against the manufacturers of Rexulti. Lawyers representing the plaintiffs will return to court in Montreal on October 31, 2025, for a hearing to seek approval of the settlement.

Background on Rexulti and Legal Proceedings

The class-action suit highlights serious concerns regarding the side effects of Rexulti, as individuals reported various impulse-control disorders linked to the medication. This case draws attention to the broader issue of pharmaceutical accountability and patient safety.

As the lawsuit progresses, it underscores the importance of ongoing monitoring of medications and their potential effects on patients’ behavior. The announcement of the settlement marks a significant step in addressing the grievances of those affected by the drug.

This report was initially published by The Canadian Press on August 23, 2025. The implications of this settlement extend beyond financial compensation, prompting discussions on the responsibilities of pharmaceutical companies in ensuring the safety and well-being of their consumers.